This Article Full Text Full Text (PDF) All Versions of this Article: 48/5/832    most recent 01.HYP.0000244083.49950.14v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ruilope, L. M. Articles by Segura, J. Search for Related Content PubMed PubMed Citation Articles by Ruilope, L. M. Articles by Segura, J. Pubmed/NCBI databases Medline Plus Health Information High Blood Pressure Related Collections Cardiovascular Pharmacology Clinical Studies Related Article

(Hypertension. 2006;48:832.)
© 2006 American Heart Association, Inc.

Editorial Commentaries

Predictors of the Evolution of Microalbuminuria

Luis M. Ruilope; Julian Segura

From the Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain.

Correspondence to Luis M. Ruilope, Hypertension Unit, Hospital 12 de Octubre, Av Córdoba s/n, 28041 Madrid, Spain. E-mail ruilope@ad-hocbox.com

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Albuminuria, either micro- or macro-, is considered as an independent cardiovascular and renal risk factor that must be determined in any patient with diabetes and with arterial hypertension. The presence of microalbuminuria has also been shown to be a risk factor of similar magnitude in the general population,¹ although the possibility of its estimation in the whole population remains as an elusive objective. Recently, 2 relevant issues related to albuminuria have been published: first, prevention of development of microalbuminuria has been demonstrated as an attainable objective in type 2 diabetic patients² and, second, diminution of the urinary excretion of albumin has been shown to be followed by a significant decrease in the development of cardiovascular events and death.³ All of these facts enhance the need to improve our knowledge on predictors of the development and evolution of microalbuminuria. Further progression to macroalbuminuria occurs in a significant number of cases, particularly, but not solely, in diabetic patients, indicating the presence of overt renal disease. Such a progression can be seen in nondiabetic patients with arterial hypertension⁴ and also in patients with advanced cardiovascular disease.⁵

The present issue of Hypertension contains a substudy of the Prevention of REnal and Vascular ENd stage Disease (PREVEND) study⁶ in which the authors analyze the parameters that determine baseline urinary albumin excretion, as well as the predictors of the response obtained with the administration of an angiotensin-converting enzyme inhibitor during the first 3 months of follow-up in a group of 384 microalbuminuric subjects with apparently normal . . . [Full Text of this Article]

Related Article:

Predictors of Angiotensin-Converting Enzyme Inhibitor–Induced Reduction of Urinary Albumin Excretion in Nondiabetic Patients

Ruud M.A. van de Wal, Ron T. Gansevoort, Pim van der Harst, Frans Boomsma, H.W. Thijs Plokker, Dirk J. van Veldhuisen, Paul E. de Jong, Wiek H. van Gilst, and Adriaan A. Voors
Hypertension 2006 48: 870-876. [Abstract] [Full Text] [PDF]